By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Vote in favor of Your #1 Home Exercise Gear: Execution and Comfort Matter - 2Doggie diversity in size and shape began at least 11,000 years ago
- 35 Must-Attempt Fascinating Dishes from Around the World
- 4Why is everyone talking about Paul Dano? George Clooney becomes the actor's latest defender in this 'time of cruelty.'
- 5True serenity: Investigating Emotional well-being and the Advantages of Contemplation
- Transcript: NASA's Jared Isaacman on "Face the Nation with Margaret Brennan," April 5, 2026
- The Force of Care: Living with Goal
- Mating injuries may lead scientists to identify dinosaurs’ sex
- What loving-kindness meditation is and how to practice it in the new year
- Do you lean your seat back on the plane? These travel pros — and real-life couple — won't do it.
- Vote In favor of Your Favored Sort Of Bevarage
- Step by step instructions to Pick the Ideal Authorize Internet Advertising Degree Program
- Rights group: At least 2,500 deaths during protest crackdown in Iran
- Old age isn’t a modern phenomenon – many people lived long enough to grow old in the olden days, too
